Increased pressure in the veins leading to the liver, known as portal hypertension (PH), accounts for the majority of medical complications and deaths associated with cirrhosis.
Therefore, a tremendous need exists to find drugs that simultaneously treat the multiple pathologies associated with chronic PH. In a study in The American Journal of Pathology, investigators report that treatment with aleglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma (PPARα/γ) agonist, reduced inflammation, vasoconstriction, angiogenesis, mucosal disruption, and tumor necrosis factor (TNF)-α overproduction in cirrhotic rats with PH. This suggests a promising new approach for treating liver cirrhosis.
To read the full story, visit: medicalexpress.com